News | January 11, 2024
Aarti Pharmalabs sets up R&D Centre in Navi Mumbai
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
Lack of technology transfer stands out as a formidable barrier
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Subscribe To Our Newsletter & Stay Updated
